|
US4960765A
(en)
*
|
1980-03-20 |
1990-10-02 |
Farmaceutisk Laboratorium Ferring A/S |
Pharmaceutical composition and method for the treatment of colitis ulcerosa and Crohn's disease by oral administration
|
|
WO1981002671A1
(en)
*
|
1980-03-20 |
1981-10-01 |
Ferring Farma Lab |
Pharmaceutical composition and method for the treatment of colitis ulcerosa and crohn's disease by oral administration
|
|
IT1222414B
(it)
*
|
1987-07-31 |
1990-09-05 |
Chiesi Farma Spa |
Composizioni farmaceutiche contenenti trapidil,loro procedimento di preparazione e relaticvo impiego terapeutico
|
|
FR2630913A1
(fr)
*
|
1988-05-09 |
1989-11-10 |
Delalande Sa |
Comprimes de sel(s) hydrosoluble(s) de diltiazem a liberation programmee et leur procede de fabrication
|
|
AT391269B
(de)
*
|
1988-12-30 |
1990-09-10 |
Burghart Kurt |
Pharmazeutische zubereitung
|
|
US5032384A
(en)
*
|
1989-01-27 |
1991-07-16 |
Block Drug Company, Inc. |
Compositions and method for the treatment of disease
|
|
HU203041B
(en)
*
|
1989-03-14 |
1991-05-28 |
Egyt Gyogyszervegyeszeti Gyar |
Process for producing pharmaceutical compositions of controlled releasing factor containing nifedipin
|
|
CA1340994C
(en)
*
|
1989-09-21 |
2000-05-16 |
Rudolf Edgar Dr. Falk |
Treatment of conditions and disease
|
|
US5639738A
(en)
*
|
1992-02-20 |
1997-06-17 |
Hyal Pharmaceutical Corporation |
Treatment of basal cell carcinoma and actinic keratosis employing hyaluronic acid and NSAIDs
|
|
CA2061703C
(en)
*
|
1992-02-20 |
2002-07-02 |
Rudolf E. Falk |
Formulations containing hyaluronic acid
|
|
US5990096A
(en)
*
|
1990-09-18 |
1999-11-23 |
Hyal Pharmaceutical Corporation |
Formulations containing hyaluronic acid
|
|
US5910489A
(en)
*
|
1990-09-18 |
1999-06-08 |
Hyal Pharmaceutical Corporation |
Topical composition containing hyaluronic acid and NSAIDS
|
|
US5824658A
(en)
*
|
1990-09-18 |
1998-10-20 |
Hyal Pharmaceutical Corporation |
Topical composition containing hyaluronic acid and NSAIDS
|
|
US5275820A
(en)
*
|
1990-12-27 |
1994-01-04 |
Allergan, Inc. |
Stable suspension formulations of bioerodible polymer matrix microparticles incorporating drug loaded ion exchange resin particles
|
|
US5817644A
(en)
*
|
1991-07-03 |
1998-10-06 |
Hyal Pharmaceutical Corporation |
Targeting of dosages of medicine and therapeutic agents
|
|
US5792753A
(en)
*
|
1991-07-03 |
1998-08-11 |
Hyal Pharmaceutical Corporation |
Compositions comprising hyaluronic acid and prostaglandin-synthesis-inhibiting drugs
|
|
US6022866A
(en)
*
|
1991-07-03 |
2000-02-08 |
Hyal Pharmaceutical Corporation |
Use of hyaluronic acid and forms to prevent arterial restenosis
|
|
US6103704A
(en)
*
|
1991-07-03 |
2000-08-15 |
Hyal Pharmaceutical Corporation |
Therapeutic methods using hyaluronic acid
|
|
WO1994007505A1
(en)
*
|
1991-07-03 |
1994-04-14 |
Norpharmco Inc. |
Use of hyaluronic acid and forms to prevent arterial restenosis
|
|
US5990095A
(en)
*
|
1991-07-03 |
1999-11-23 |
Hyal Pharmaceutical Corporation |
Use of hyaluronic acid and forms to prevent arterial restenosis
|
|
US5977088A
(en)
*
|
1991-07-03 |
1999-11-02 |
Hyal Pharmaceutical Corporation |
Formulations containing hyaluronic acid
|
|
US6136793A
(en)
*
|
1992-02-20 |
2000-10-24 |
Hyal Pharmaceutical Corporation |
Formulations containing hyaluronic acid
|
|
CA2061567C
(en)
*
|
1992-02-20 |
1998-02-03 |
Rudolf E. Falk |
Use of hyaluronic acid to repair ischemia reperfusion damage
|
|
US6218373B1
(en)
|
1992-02-20 |
2001-04-17 |
Hyal Pharmaceutical Corporation |
Formulations containing hyaluronic acid
|
|
US6114314A
(en)
*
|
1992-02-21 |
2000-09-05 |
Hyal Pharmaceutical Corp. |
Formulations containing hyaluronic acid
|
|
US5767106A
(en)
*
|
1992-02-21 |
1998-06-16 |
Hyal Pharmaceutical Corporation |
Treatment of disease and conditions associated with macrophage infiltration
|
|
DE4206857C2
(de)
*
|
1992-03-05 |
1996-08-29 |
Stockhausen Chem Fab Gmbh |
Polymerzusammensetzung, Absorptionsmaterialzusammensetzung, deren Herstellung und Verwendung
|
|
EP0700415B1
(de)
*
|
1993-05-03 |
1997-08-06 |
Stockhausen GmbH & Co. KG |
Polymerzusammensetzung, absorptionsmaterialzusammensetzung, deren herstellung und verwendung
|
|
US6746691B2
(en)
|
1993-09-20 |
2004-06-08 |
Kos Pharmaceuticals, Inc. |
Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics
|
|
US6818229B1
(en)
|
1993-09-20 |
2004-11-16 |
Kos Pharmaceuticals, Inc. |
Intermediate release nicotinic acid compositions for treating hyperlipidemia
|
|
US6676967B1
(en)
|
1993-09-20 |
2004-01-13 |
Kos Pharmaceuticals, Inc. |
Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia
|
|
US6080428A
(en)
|
1993-09-20 |
2000-06-27 |
Bova; David J. |
Nicotinic acid compositions for treating hyperlipidemia and related methods therefor
|
|
US6129930A
(en)
|
1993-09-20 |
2000-10-10 |
Bova; David J. |
Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night
|
|
US6129931A
(en)
*
|
1998-09-03 |
2000-10-10 |
Isp Investments Inc. |
Controlled-release, drug-delivery tableted composition including a complex between poly(maleic diacid-alkyl vinyl ether) and polyvinylpyrrolidone
|
|
FR2802424B1
(fr)
†
|
1999-12-17 |
2002-02-15 |
Adir |
Comprime matriciel permettant la liberation prolongee de trimetazidine apres administration par voie orale
|
|
CA2924200C
(en)
*
|
2005-10-12 |
2017-09-05 |
Proventiv Therapeutics, Llc |
Methods and articles for treating 25-hydroxyvitamin d insufficiency and deficiency
|
|
CA2882048C
(en)
|
2006-02-03 |
2020-03-24 |
Proventiv Therapeutics, Llc |
Treating vitamin d insufficiency and deficiency with 25-hydroxyvitamin d2 and 25-hydroxyvitamin d3
|
|
ES2497494T3
(es)
|
2006-06-21 |
2014-09-23 |
Opko Renal, Llc |
Método de tratamiento y prevención del hiperparatiroidismo secundario
|
|
WO2008005534A2
(en)
*
|
2006-07-06 |
2008-01-10 |
Forest Laboratories, Inc. |
Orally dissolving formulations of memantine
|
|
AU2007295894B2
(en)
*
|
2006-09-13 |
2013-10-17 |
Enhance Skin Products, Inc. |
Cosmetic composition for the treatment of skin and methods thereof
|
|
EA009810B1
(ru)
*
|
2006-12-26 |
2008-04-28 |
Закрытое Акционерное Общество "Канонфарма Продакшн" |
Матрица для изготовления таблетированной лекарственной формы и способ лечения
|
|
WO2009047644A2
(en)
*
|
2007-04-25 |
2009-04-16 |
Cytochroma Inc. |
Method of treating vitamin d insufficiency and deficiency
|
|
WO2008134523A1
(en)
|
2007-04-25 |
2008-11-06 |
Proventiv Therapeutics, Llc |
Method of safely and effectively treating and preventing secondary hyperparathyroidism in chronic kidney disease
|
|
WO2008134518A2
(en)
*
|
2007-04-25 |
2008-11-06 |
Cytochroma Inc. |
Methods and compounds for vitamin d therapy
|
|
KR20190028822A
(ko)
|
2007-04-25 |
2019-03-19 |
사이토크로마 인코포레이티드 |
비타민 ｄ 화합물과 밀랍성 담체를 포함하는 경구 조절성 방출 조성물
|
|
US8962239B2
(en)
|
2008-04-02 |
2015-02-24 |
Opko Renal, Llc |
Methods useful for vitamin D deficiency and related disorders
|
|
FR2936952A1
(fr)
*
|
2008-10-09 |
2010-04-16 |
Monique Bellec |
Administration par voie orale de medicaments et complements nutritionnels
|
|
CA2779242A1
(en)
*
|
2009-10-27 |
2011-05-12 |
Halosource, Inc. |
Packaging formulation for preventing the insolubility of chitosan-containing compositions
|
|
PT2552484T
(pt)
|
2010-03-29 |
2020-04-03 |
Opko Ireland Global Holdings Ltd |
Métodos e composições para redução dos níveis de parafróides
|
|
BG1345U1
(bg)
*
|
2010-05-20 |
2010-08-31 |
"Адифарм" Ад |
Лекарствена форма с изменено освобождаване
|
|
KR101847947B1
(ko)
|
2013-03-15 |
2018-05-28 |
옵코 아이피 홀딩스 Ⅱ 인코포레이티드 |
안정화되고 변형된 비타민 ｄ 방출 제형
|
|
EP3193925A2
(de)
|
2014-08-07 |
2017-07-26 |
OPKO Ireland Global Holdings, Ltd. |
Adjunktive therapie mit 25-hydroxyvitamin d
|
|
IL290855B1
(en)
|
2016-03-28 |
2024-02-01 |
Eirgen Pharma Ltd |
Treatment methods using vitamin D
|
|
CN109568283B
(zh)
*
|
2018-12-28 |
2020-08-28 |
地奥集团成都药业股份有限公司 |
一种硝苯地平缓释片及其制备方法
|